• We have finished WP 1, which main goal has been to mature the AI-driven clinical decision-support tool to enable early intervention using predictive analytics. We have done this by automating ECG assessment and by providing clinicians with a holistic view of the patients’ status. We now suggest medical diagnoses based on the morphology of the heart rhythms in our platform. We have drawn on several competencies within the team to reach this milestone, both within data science, software engineering and design. All the deliverables and milestones have been completed.
• We have finished WP2 by extending our capabilities to interpret device transmissions from all cardiac device types and manufacturers to become fully device agnostic. In addition, we have accomplished a fully automated onboarding flow for patients, and support provision per-customer isolated and secure deployment. Furthermore, we now have a functioning EHR integration using the SMART on FHIR protocols.
• We obtained regulatory approval in accordance with Medical Device Directive 93/42/EEC, Annex VII.
• In obtaining our CE-mark and during the regulatory audit, we presented the clinical documentation, which was found to be enough documentation in terms of establishing enough trust in the results and potential side effects of our product, which was the intention with WP 3.
• As for the plan to become regulatory compliant for the coming changes from MDD to MDR in 2024, we have started working with our regulatory consultants to engage. The necessary documents for the clinical evaluation will be in place during 2023, in time to be part of the basis for MDR compliance.
• We have finished WP4 as we can conclude on the management of the project, that all milestones and deliverables have been completed. We periodically reviewed the risk table and managed unforeseen risks, as described in the Periodic Report.